A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
A study for patients with recurrent glioblastoma or anaplastic astrocytoma using study drug Toca 511
Sponsor: Tocagen
Enrolling: Male and Female Patients
IRB Number: AAAQ0959
U.S. Govt. ID: NCT02414165
Contact: Fabio Iwamoto, MD: 212-304-5485 / fi2146@cumc.columbia.edu
Additional Study Information: This is a research study to test the effectiveness of Toca 511/Toca FC, an experimental drug, for treatment of recurring brain tumors compared to current standard of care. The study will enroll 370 subjects age 18-85 years who choose to undergo removal of the tumor a second time. At the time of surgery patients will be randomly assigned in a 1:1 ratio to receive either the experimental drug or the standard of care. Treatment will begin approximately 6 weeks after surgery. Blood, tumor, and cerebrospinal fluid will be collected to determine the effectiveness of the new drug. Given the tendency of malignant brain tumors to recur and and the limited success of the current standard of care, Toca 511/Toca FG has the potential for improving the outcome of patients with recurring brain tumors.
This study is closed
Fabio Iwamoto, MD
Do You Qualify?
Have you been diagnosed with glioblastoma? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Fabio Iwamoto, MD